1. Home
  2. ELDN vs SGC Comparison

ELDN vs SGC Comparison

Compare ELDN & SGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • SGC
  • Stock Information
  • Founded
  • ELDN 2004
  • SGC 1920
  • Country
  • ELDN United States
  • SGC United States
  • Employees
  • ELDN N/A
  • SGC N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • SGC Apparel
  • Sector
  • ELDN Health Care
  • SGC Consumer Discretionary
  • Exchange
  • ELDN Nasdaq
  • SGC Nasdaq
  • Market Cap
  • ELDN 178.4M
  • SGC 155.7M
  • IPO Year
  • ELDN N/A
  • SGC N/A
  • Fundamental
  • Price
  • ELDN $3.67
  • SGC $11.28
  • Analyst Decision
  • ELDN Strong Buy
  • SGC Strong Buy
  • Analyst Count
  • ELDN 2
  • SGC 3
  • Target Price
  • ELDN $12.50
  • SGC $17.00
  • AVG Volume (30 Days)
  • ELDN 849.2K
  • SGC 48.3K
  • Earning Date
  • ELDN 08-18-2025
  • SGC 08-05-2025
  • Dividend Yield
  • ELDN N/A
  • SGC 4.90%
  • EPS Growth
  • ELDN N/A
  • SGC N/A
  • EPS
  • ELDN N/A
  • SGC 0.45
  • Revenue
  • ELDN N/A
  • SGC $563,931,000.00
  • Revenue This Year
  • ELDN N/A
  • SGC N/A
  • Revenue Next Year
  • ELDN N/A
  • SGC $4.31
  • P/E Ratio
  • ELDN N/A
  • SGC $25.42
  • Revenue Growth
  • ELDN N/A
  • SGC 2.28
  • 52 Week Low
  • ELDN $2.38
  • SGC $9.11
  • 52 Week High
  • ELDN $5.54
  • SGC $20.75
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 67.56
  • SGC 64.19
  • Support Level
  • ELDN $3.64
  • SGC $10.46
  • Resistance Level
  • ELDN $3.93
  • SGC $10.96
  • Average True Range (ATR)
  • ELDN 0.23
  • SGC 0.36
  • MACD
  • ELDN 0.05
  • SGC 0.01
  • Stochastic Oscillator
  • ELDN 71.91
  • SGC 79.23

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About SGC Superior Group of Companies Inc.

Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.

Share on Social Networks: